When Manufacturing Capacity Outpaces Regulatory Approvals: Planning for Global Growth

The Challenge: Rapid Growth Meets Regulatory Complexity

For a fast-growing biotech company with recently approved products in the US, Europe, and Japan, expanding into multiple markets was an exciting milestone. But faster-than-expected growth also brought new supply chain challenges.
‍

To keep pace with increasing demand, the company needed to expand its Drug Product (DP) manufacturing capacity by adding production sites within its existing Contract Manufacturing Organization (CMO).
‍

While the additional sites would provide much-needed capacity, each site required regulatory approval before its products could be supplied to a given market. And those approvals would not necessarily happen at the same time.
‍

A site might be approved to manufacture Drug Product for the US market first, while approval for Europe or Japan could come months later.
‍

This created a complex planning situation. Drug Product manufactured at each site could only be supplied to markets where the necessary regulatory approvals had been obtained. As approvals were granted at different times, the available supply options would change throughout the planning horizon.
‍

The supply chain team needed to plan not only how much product to manufacture and where, but also when each manufacturing site's output would become eligible to serve different markets.
‍

With multiple manufacturing sites, growing global demand, and approval timelines that could shift, maintaining an accurate supply plan became increasingly challenging.

The Solution: Building Regulatory Constraints into the Supply Plan

ABC-Plan's Master Planner allowed the supply chain team to incorporate these regulatory restrictions directly into its planning model.
‍

Using ABC-Plan's flexible user interface, planners could configure the regulatory requirements associated with each manufacturing site and destination market.
‍

More importantly, the expected regulatory approval timelines could be incorporated into the product structure as time-phased planning constraints.
‍

For example, Drug Product manufactured at a particular site might initially be eligible to supply only the US market. Once European approval became effective, that site's production could also be allocated to European demand. Japan could be added according to its own approval timeline.
‍

This gave the team a more accurate view of available supply options throughout the planning horizon, rather than relying on a static picture of manufacturing capacity.
‍

Planners could also adjust approval assumptions to evaluate how regulatory delays or accelerated approvals might affect supply availability and future manufacturing decisions.

End-to-End Optimization Across the Supply Network

Managing regulatory restrictions was only one part of the equation. The company still needed to determine the best way to meet growing demand while managing inventory and manufacturing constraints.
‍

With ABC-Plan's Master Planner, the team could run end-to-end, constraint-based optimization across its supply network with a single click.
‍

The optimization engine considered demand requirements, available manufacturing capacity, regulatory restrictions, inventory positions, and other planning constraints to generate planned orders across material levels and planning nodes.
‍

Rather than manually adjusting individual production and supply plans whenever a constraint changed, planners could evaluate the impact across the entire supply network in one integrated planning run.
‍

This was particularly valuable as new manufacturing sites became eligible to supply additional markets. The system could account for the expanded supply options and generate updated plans based on the latest assumptions.
‍

The goal was not simply to produce more Drug Product. It was to determine how much to produce, at which site, and when, while balancing the risk of shortages against the cost of excess inventory.

The Outcome: A More Complete View of Global Supply

By incorporating site-specific regulatory approvals and their effective dates into ABC-Plan, the company gained a planning model that better reflected the realities of its expanding manufacturing network.
‍

The solution enabled the supply chain team to:
‍

· Manage regulatory constraints by site and market, ensuring planned supply follows the applicable approval requirements.

· Incorporate time-phased approval schedules to reflect how supply options change throughout the planning horizon.

· Evaluate approval delays and alternative scenarios to understand their impact on future supply.

· Generate end-to-end optimized planned orders across material levels, manufacturing sites, and planning nodes.

· Balance stockout and excess inventory risks while supporting growing commercial demand.
‍

Perhaps most importantly, the team could see the broader supply implications of regulatory and manufacturing changes without having to manually reconcile multiple disconnected plans.
‍

As the company continued to expand its manufacturing capacity, ABC-Plan provided a way to manage increasing complexity while maintaining an integrated view of global supply.

Looking Ahead: Planning for Growth in a Regulated World

For commercial-stage biotech companies, expanding manufacturing capacity is not simply a matter of adding production lines or new sites. Regulatory approvals determine where manufactured products can be distributed, and those restrictions can change over time.
‍

As global demand grows, supply planning must account for both physical manufacturing capabilities and regulatory eligibility.
‍

ABC-Plan's flexible product structure, time-phased constraints, and end-to-end optimization allow companies to plan around these realities without losing visibility across their supply networks.
‍

In this case, the company was able to build a supply planning model that reflected not only where Drug Product could be manufactured, but also when and where it could be supplied—helping the team navigate rapid growth while balancing inventory investment and supply risk.